PharmaCyte Biotech, Inc.
PMCBNasdaq
$0.63
↓ -4.1%Jul 17 close · end-of-day
Price
1Y↓ -43.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.9M
Enterprise Value
-$14.7M
P/E
—
P/S
—
P/B
0.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$0.00
Net Income (TTM)
-$3.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-8.6%
ROIC
-24.2%
Debt / Equity
—
Net Cash
$20.5M
Return 1Y
-37.9%
Company profile
PharmaCyte Biotech, Inc. focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer.
- CEO
- Joshua N. Silverman
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4
- Headquarters
- California
- Website
- pharmacyte.com
Earnings
PMCB Q3 2026 Earnings
Period ends 2026-01-31
MetricActualYoY
Revenue$0.00—
Diluted EPS-$0.17↓ -61.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$3.6M | -$4.4M | -$6.5M | -$8.5M | -$4.4M |
| Net income | -$3.6M | -$4.2M | -$4.3M | $333,763.00 | $30.7M |
| Diluted EPS | -$2.45 | -$0.27 | -$0.22 | -$1.80 | $3.19 |
| Operating cash flow | -$3.3M | -$4.1M | -$3.8M | -$2.2M | -$3.0M |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.2M | -$1.3M | -$1.1M | -$960,252.00 | -$1.0M | -$848,305.00 | -$1.4M | -$2.1M |
| Net income | $1.3M | $23.4M | -$1.5M | -$3.0M | $11.7M | -$8.4M | -$7.4M | $746,860.00 |
| Diluted EPS | -$0.35 | $1.90 | -$0.39 | -$0.44 | $2.12 | -$1.23 | -$1.24 | -$0.17 |
| Operating cash flow | -$332,958.00 | -$373,297.00 | -$1.1M | -$509,893.00 | -$1.0M | -$2.0M | -$979,523.00 | -$786,848.00 |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Aug 20, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-07 | Silverman Joshua· CEO and President | Buy | 40,000 | $0.83 | $33,316.00 | filing |
| 2026-01-07 | SCHECHTER JONATHAN | Buy | 20,000 | $0.84 | $16,872.00 | filing |
| 2026-01-06 | Silverman Joshua· CEO and President | Buy | 30,000 | $0.79 | $23,667.00 | filing |
| 2026-01-06 | SCHECHTER JONATHAN | Buy | 20,000 | $0.79 | $15,808.00 | filing |
| 2026-01-05 | Silverman Joshua· CEO and President | Buy | 30,000 | $0.78 | $23,493.00 | filing |
| 2026-01-05 | SCHECHTER JONATHAN | Buy | 20,000 | $0.78 | $15,552.00 | filing |
| 2025-12-12 | Silverman Joshua· CEO and President | Tax withholding | 258,750 | $1.02 | $263,925.00 | filing |
| 2025-12-12 | Silverman Joshua· CEO and President | Award | 575,000 | $0.00 | $0.00 | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.